Eptifibatide patient counseling information: Difference between revisions

Latest revision as of 02:45, 22 July 2014

Redirect to:

@@ Line 1: / Line 1: @@
-__NOTOC__
+#REDIRECT [[Eptifibatide#Patient Counseling Information]]
-{{Eptifibatide}}
-{{CMG}}; {{AE}} {{SS}}
-==Patient Counseling Information==
-Instruct patients to inform the doctor or healthcare provider about any medical conditions, medications, and allergies.
-Manufactured for: Merck Sharp & Dohme Corp., a subsidiary of
-MERCK & CO., INC., Whitehouse Station, NJ 08889, USA
-Manufactured by:
-Patheon Italia S.p.A, Ferentino, 03013, Italy
-U.S. Patent Nos. 5,686,570; 5,747,447; and 5,756,451.
-INTEGRILIN is a registered trademark of Millennium Pharmaceuticals, Inc.
-USPI-I-69361303R011<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = INTEGRILIN (EPTIFIBATIDE) INJECTION, SOLUTION [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ad82e30-50d8-450c-8a2a-b4b507ed1ce2 | publisher =  | date =  | accessdate = 5 February 2014 }}</ref>
-==References==
-{{Reflist|2}}
-[[Category:Antiplatelet drugs]]
-[[Category:Cardiovascular Drugs]]
-[[Category:Drugs]]
-{{WikiDoc Help Menu}}
-{{WikiDoc Sources}}